In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

FibroGen, Inc. Trade Record

NASDAQ:FGEN FibroGen, Inc stock gains 7.74% Exit Jan 4, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart FGEN Dec 20, 2017, priceSeries
About FibroGen, Inc

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
91.30
Entry Date
Dec 20, 2017
Entry Price
44.55
Sell Date
Jan 4, 2018
Sell Price
48.00
Net Gain
7.74%
Hold Time
9 Trading Days